NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

• Market Cap: $3.98B
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 113,390,800
• 10 Day Avg. Volume: 1,117,133
• 30 Day Avg. Volume: 1,085,460
• PEG Ratio: -0.53
• Price to Book (P/B): 3.20
• Price to Sales (P/S): 53.22
• P/FCF Ratio: -15.23
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 76.05
• Enterprise Value/Gross Profit: 76.05
• Enterprise Value/Ebitda: -9.30
• 1Y Price Target: $48.43
• Price Target Upside: 37.94% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -1.47
• Revenue Forecast (FY): $27.10M

• Rating: 58 Neutral
• Price Target: $36.00 ▲(2.53% Upside)

The stock score is primarily influenced by the company's strong technical performance, indicating positive market momentum. However, financial performance is a concern due to ongoing operational losses and negative cash flows, typical of biotech firms in early stages. Valuation is challenging due to negative earnings, but the company's ability to raise capital provides some stability.

Positive Factors

Regulatory Milestone

EMA validation is a critical step towards commercialization in Europe, expanding market reach and enhancing competitive positioning in the cardiovascular treatment sector.

Clinical Trial Success

Successful trial results position NAMS as a leader in both cardiovascular and neurodegenerative disease treatment, potentially increasing market share and revenue.

Strategic Partnerships

The partnership with Menarini enhances distribution capabilities and operational efficiency, supporting long-term growth and market penetration.

Negative Factors

Profitability Challenges

Persistent operational losses due to high R&D costs can strain financial resources, delaying profitability and impacting long-term financial health.

Negative Cash Flow

Negative cash flow indicates ongoing cash burn, which may necessitate further capital raising, potentially diluting existing shareholders.

Volatile Revenue

Revenue volatility can complicate financial planning and investor confidence, impacting the company's ability to sustain long-term growth.

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

How the Company Makes Money

NewAmsterdam Pharma generates revenue primarily through the commercialization of its pharmaceutical products, which are sold to healthcare providers, hospitals, and pharmacies. The company may also engage in strategic partnerships with larger pharmaceutical firms for joint development and marketing of its drug candidates, which can provide additional income through upfront payments and royalties on sales. Research grants and funding from government and private entities for clinical trials and product development may also contribute to its revenue. Additionally, licensing agreements for its intellectual property could serve as significant revenue streams, enhancing the company's financial stability.

NewAmsterdam Pharma Company Financial Statement Overview

Summary

NewAmsterdam Pharma Company exhibits typical characteristics of a biotech firm with high R&D expenses leading to operational losses. While revenue growth is promising, profitability remains a challenge. The balance sheet is strong with low leverage, providing stability. Cash flows are negative, but capital raising efforts support liquidity. The company must focus on achieving profitability to ensure long-term sustainability.

Income Statement

The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.

Cash Flow

Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.24M	45.56M	14.09M	102.69M	0.00	0.00
Gross Profit	35.24M	45.56M	14.09M	102.69M	0.00	0.00
EBITDA	-288.10M	-241.49M	-176.86M	-22.34M	-41.37M	-6.63M
Net Income	-221.07M	-241.60M	-176.94M	-22.63M	-41.78M	-7.02M
Balance Sheet
Total Assets	786.43M	864.62M	347.10M	478.50M	67.99M	139.87M
Cash, Cash Equivalents and Short-Term Investments	702.95M	834.19M	340.45M	467.73M	60.38M	1.37M
Total Debt	266.00K	448.00K	60.00K	126.00K	186.51K	0.00
Total Liabilities	58.36M	107.12M	58.70M	48.43M	11.36M	12.41M
Stockholders Equity	728.07M	757.50M	288.39M	430.07M	56.63M	127.46M
Cash Flow
Free Cash Flow	-144.54M	-159.24M	-141.24M	10.44M	-29.54M	―
Operating Cash Flow	-144.39M	-158.56M	-141.22M	10.66M	-29.51M	―
Investing Cash Flow	-215.95M	-62.85M	-24.00K	-221.00K	-24.00K	―
Financing Cash Flow	472.45M	659.51M	8.91M	391.90M	84.70M	13.92M

NewAmsterdam Pharma Company Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 35.11
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Neutral. The current price of 35.11 is below the 20-day moving average (MA) of 36.86, below the 50-day MA of 37.19, and above the 200-day MA of 25.70, indicating a neutral trend. The MACD of -0.75 indicates Positive momentum. The RSI at 45.59 is Neutral, neither overbought nor oversold. The STOCH value of 27.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NAMS.

NewAmsterdam Pharma Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	72 Outperform	$3.27B	96.32	7.39%	―	55.68%	―
NAMS	58 Neutral	$3.98B	-17.19	-39.94%	―	―	―
VKTX	53 Neutral	$3.98B	-16.61	-29.23%	―	―	-126.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XENE	48 Neutral	$3.41B	―	-45.14%	―	―	-38.30%
IMVT	45 Neutral	$5.38B	-9.43	-95.93%	―	―	-27.70%
SLNO	37 Underperform	$2.57B	-25.98	-20.66%	―	―	44.84%

NewAmsterdam Pharma Company Corporate Events

NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone

On November 5, 2025, NewAmsterdam Pharma announced its third-quarter financial results and provided a corporate update. The company reported a significant regulatory milestone with the European Medicines Agency’s acceptance of marketing authorization applications for obicetrapib and its fixed-dose combination with ezetimibe. Despite a decrease in revenue and an increase in net loss compared to the previous year, NewAmsterdam continues to advance its clinical development strategy and build global infrastructure to support the potential launch of obicetrapib. The company also highlighted its ongoing trials and upcoming milestones, emphasizing its commitment to providing a differentiated therapy in the cardiovascular market.